Merus N.V. (MRUS) – Globe Newswire
-
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
-
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
-
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
-
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
-
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
-
Merus to Participate in Upcoming Investor Conferences
-
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
-
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
-
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
-
Merus to Participate in Upcoming Investor Conferences
-
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
-
Merus Announces Business Update Conference Call
-
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
-
Merus to Participate in Upcoming Investor Conferences
-
Merus Announces Pricing of Public Offering of Common Shares
-
Merus N.V. Announces Proposed Public Offering of Common Shares
-
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
-
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 202
-
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
-
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
-
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
-
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
-
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
-
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
-
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
-
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
-
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
-
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
-
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
-
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
-
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
-
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
-
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
-
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
-
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
-
Merus to Participate in Upcoming Investor Conferences
-
Merus to Participate in Upcoming Investor Conferences
-
CORRECTING and REPLACING --Merus Provides 2023 Outlook
-
CORRECTING and REPLACING --Merus Provides 2023 Outlook
-
Merus Provides 2023 Outlook
-
Merus Provides 2023 Outlook
-
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
-
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
-
Merus Announces Financial Results for the Third Quarter and Provides Business Update
-
Merus Announces Financial Results for the Third Quarter and Provides Business Update
-
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
-
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
Back to MRUS Stock Lookup
